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Background: Germline and somatic mutations in STK11, the gene encoding the serine/threonine kinase LKB1, are
strongly associated with tumorigenesis. While loss of LKB1 expression has been linked to breast cancer, the
mechanistic role of LKB1 in regulating breast cancer development, metastasis, and tumor metabolism has remained
unclear.
Methods: We have generated and analyzed transgenic mice expressing ErbB2 in the mammary epithelium of LKB1
wild-type or LKB1-deficient mice. We have also utilized ErbB2-expressing breast cancer cells in which LKB1 levels
have been reduced using shRNA approaches. These transgenic and xenograft models were characterized for the
effects of LKB1 loss on tumor initiation, growth, metastasis and tumor cell metabolism.
Results: We demonstrate that loss of LKB1 promotes tumor initiation and induces a characteristic shift to aerobic
glycolysis (‘Warburg effect’) in a model of ErbB2-mediated breast cancer. LKB1-deficient breast cancer cells display
enhanced early tumor growth coupled with increased cell migratory and invasive properties in vitro. We show that
ErbB2-positive tumors deficient for LKB1 display a pro-growth molecular and phenotypic signature characterized by
elevated Akt/mTOR signaling, increased glycolytic metabolism, as well as increased bioenergetic markers both
in vitro and in vivo. We also demonstrate that mTOR contributes to the metabolic reprogramming of LKB1-deficient
breast cancer, and is required to drive glycolytic metabolism in these tumors; however, LKB1-deficient breast cancer
cells display reduced metabolic flexibility and increased apoptosis in response to metabolic perturbations.
Conclusions: Together, our data suggest that LKB1 functions as a tumor suppressor in breast cancer. Loss of LKB1
collaborates with activated ErbB2 signaling to drive breast tumorigenesis and pro-growth metabolism in the
resulting tumors.
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STK11 was identified in 1998 as a novel tumor suppres-
sor gene in patients with Peutz-Jeghers syndrome (PJS)
[1], an autosomal, dominant disorder characterized by
the presence of pigmented macules on the skin and
mouth, coupled with the growth of benign polyps in the
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reproduction in any medium, provided the orare the most common malignancies associated with PJS,
patients also exhibit an 18-fold increased risk of devel-
oping epithelial cancers, including those of the breast
[3]. The risk of developing breast cancer in PJS patients
is 8% at the age of 40 and reaches 45% by the age of 70;
which corresponds to a risk profile similar to patients
with BRCA1 and BRCA2 mutations [3]. Consistent with
these clinical observations, recent studies have linked
LKB1 loss to enhanced breast cancer tumorigenesis in
mice [4-6]. Indeed, the loss of LKB1, in the absence of a
transforming oncogene, results in the emergence of
mammary tumors with low penetrance and long latencyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mary tumor formation in response to various onco-
genes [5,6]. However, the functional role of LKB1 in
restricting breast cancer initiation and growth is not
fully understood.
The STK11 gene encodes the protein kinase LKB1, a
serine threonine kinase that plays a multi-faceted role in
cell biology [7]. One of the best-characterized targets of
LKB1 is the energy sensor AMP-activated protein kinase
(AMPK). LKB1 phosphorylates and activates AMPK in
response to energetic stress [8,9], leading to changes in
cell metabolism designed to conserve cellular ATP. One
of the main targets of LKB1 signaling is mTOR complex
1 (mTORC1). LKB1-dependent activation of AMPK in-
hibits mTORC1 activity via dual regulation of the tuber-
ous sclerosis complex (TSC) [10] and the mTORC1
scaffold protein Raptor [11]. The diversity of LKB1-
dependent biological functions may lie in the fact that
LKB1 phosphorylates and regulates 12 AMPK-related ki-
nases in addition to AMPK [12]. Given its diversity of
kinase targets, LKB1 has been characterized as a ‘master’
kinase that regulates diverse cellular processes, including
cell polarity, energy metabolism, apoptosis, and cell pro-
liferation [7,13-15]. Importantly, all of these processes
play a role in cancer initiation and progression, and may
contribute at some level to the tumor suppressor effects
of LKB1.
To investigate the functional role of LKB1 in breast
cancer development and progression, we developed an
LKB1-deficient mouse model of ErbB2-induced mam-
mary tumorigenesis [16]. ErbB2 is a receptor tyrosine
kinase overexpressed in 25% to 30% of human breast
cancers, drives mammary tumor formation, and defines
the HER2 subtype, a poor-prognosis form of breast can-
cer [17]. Here we report that deleting LKB1 expression
in mammary epithelium harboring activating mutations
in ErbB2 promotes increased tumor initiation and en-
hanced growth of early-stage mammary tumors. Re-
duced LKB1 expression is associated with diminished
cell-to-cell contact and enhances the migratory and in-
vasive properties of established ErbB2-driven breast can-
cer cells. Interestingly, LKB1-deficient ErbB2-positive
tumors displayed a pro-growth molecular signature char-
acterized by elevated Akt/mTORC1 and reduced AMPK
signaling. LKB1-null, ErbB2-positive tumors displayed a
metabolic phenotype characteristic of the Warburg effect
in vitro and displayed heightened bioenergetic markers
both in vitro and in vivo. Induction of the Warburg effect
in these tumors is regulated, in part, by elevated mTORC1
signaling. Finally, the constitutive activation of mTORC1
signaling that accompanies LKB1 loss sensitizes breast
cancer cells to apoptosis following metabolic challenge,
such as glucose restriction. Together our data suggest that
LKB1 loss cooperates with ErbB2 to promote primarytumor development and that loss of LKB1 signaling pro-




FVB mice bearing floxed LKB1 alleles [18] were obtained
from the National Cancer Institute (strain number:
01XN2). These mice were bred with MMTV/NIC trans-
genic mice previously generated in the laboratory of
Dr. William J. Muller [19]. Mice were sacrificed when pri-
mary tumors reached maximal allowable volumes (6 to 8
weeks after the first palpation) and portions of each tumor
were flash frozen in liquid nitrogen or fixed and embed-
ded in paraffin. Mice were housed in facilities managed by
the McGill University Animal Resources Centre and all
animal experiments were conducted under ananimal use
protocol approved by McGill University and developed in
accordance with guidelines established by the Canadian
Council on Animal Care.
Cell lines, cell culture, and DNA constructs
The NIC cell line was established from a primary mammary
tumor derived from the MMTV/NIC transgenic mouse
[19]. Cells were maintained in DMEM supplemented with
5% FBS and 1× mammary epithelial growth supplement
(Invitrogen, Burlington, ON, Canada). A shRNA targeting
mouse LKB1 (sequence: 5′-AGGTCAAGATCCTCAAGA
AGAA-3′) was cloned into the murine stem cell virus
P2Gm plasmid (Addgene, 22699, Cambridge, MA, USA)
using EcoRI and XhoI restriction sites. Retroviruses were
generated in vesicular stomatitis virus cells according to the
manufacturer’s instruction (CloneTech, Mountain View,
CA, USA). Retrovirus-infected cells were selected by culture
in 1 μg/ml puromycin and sorted by flow cytometry for
green fluorescent protein (GFP) expression.
3D cell culture, migration and invasion assays
3D Matrigel cultures were established using 8-well
chamber slides (NUNC, Rockford, IL, USA). In each
well, 110 μl of Matrigel (BD Biosciences, Mississauga,
ON, Canada) was plated and allowed to solidify at 37°C
for 30 min. Subsequently, 1,000 mono-dispersed cells
were mixed in 300 μl culture medium containing 10%
FBS and 2% Matrigel and seeded on top of the Matrigel.
The medium was changed every three days and cells an-
alyzed after 9 days of culture by immunofluorescent
staining.
Migration and invasion of NIC cells was assessed by
plating 2 × 104 and 1 × 105 cells, respectively, in serum-
free media, onto xCELLigence CIM plates (Roche Applied
Science, Laval, QC, Canada). The rate of migration and in-
vasion was monitored for 24 hours and calculated
according to the manufacturer’s protocol. The data shown
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ments performed in duplicate.
In vivo tumor cell assays
To assess primary tumor growth, 1 × 106 cells from each
cell population (NIC-parental, NIC-FF (firefly luciferase)
and NIC-LKB1 KD (knockdown)) were injected into the
mammary fat pad (n = 10 animals per cell line) as previ-
ously described [20]. Experimental lung metastasis as-
says were conducted and the quantification of lung
metastatic burden was performed as previously de-
scribed [20]. Experimental metastasis assays were
performed by injecting 5 × 105cells directly into the lat-
eral tail vein of severe combined immunodeficiency
(SCID)/beige mice (n = 10 animals per cell line). All
mice were sacrificed four weeks post-injection. The lung
metastatic burden was also determined.
Reverse phase protein arrays (RPPA)
Tumor lysates were prepared and processed following
the protocol available on the MD Anderson Cancer Cen-
ter website [21]. Statistical analysis of the RPPA data is
described in Additional file 1.
Immunoblotting
NIC breast cancer cells were cultured to 80% confluency
and lysed in ice cold AMPK lysis buffer [22] supplemented
with protease and phosphatase inhibitors (Roche, Laval,
QC, Canada), dithiothreitol(1 μg/ml), and benzamidine
(1 μg/ml). Immunoblots were performed as previously de-
scribed [20] using several primary antibodies (Additional
file 2: Table S1).
Analysis of metabolites by liquid chromatography and
mass spectrometry (LC-MS)
Tumor samples (50 mg), or cell lines cultured for 24
hours, were extracted in a solution of 50% acetonitrile
(ACN) and injected onto an Agilent 6430 triple
quadrupole LC-MS system for targeted metabolite ana-
lysis (ATP, ADP, AMP, creatine, glucose, and lactate).
Chromatography was performed using a 1290 Infinity
ultra-performance liquid chromatography system (Agilent
Technologies, Santa Clara, CA, USA) consisting of vac-
uum degasser, auto-sampler and a binary pump. The col-
umn temperature was maintained at 10°C and the
injection volume was 5 μl. Separation was achieved using
a Cogent Diamond Hydride column (4.0 μm, 2.1 × 100.0
mm) (MicroSolv Technology, Eatontown, NJ, USA) using
a flow rate of 0.4 ml/min and a Cogent Diamond Hydride
guard column (4.0 μm, 2.0 × 20.0 mm) (MicroSolv
Technology, Eatontown, NJ, USA). The chromatography
run started with a 2 minute hold in 97% solution B (15 mM
ammonium formate in 85% ACN/15% H2O, pH 5.8) and
3% solution A (15 mM ammonium formate in H2O, pH5.8). Subsequently, samples were subjected to a 5 minute
gradient down to 70% solution B, followed by a 3 min step
with 98% solution A. A subsequent re-equilibration time
(6 min) was performed prior to the next injection. The
mass spectrometer is equipped with an electrospray
ionization source and samples were analyzed in positive
mode for creatine, glucose, and lactate and in negative
mode for ATP, ADP, and AMP. Data were quantified by
integrating the area under the curve of each optimized
multiple reaction monitoring transition using authentic
standards for each metabolite. Absolute quantification was
performed using calibration curves processed with Agilent
MassHunter Quantitative Analysis software. Transitions
in negative ionization mode for quantifier and qualifier
ions were, respectively: 506.0 → 158.9 and 506.0 → 78.9
for ATP; 426.0 → 134 and 426.0 → 79 for ADP; 346.0 →
97 and 346.0 → 78.9 for AMP; 179.0 → 89.0 and 179 →
59 for glucose; and 89 → 43.1 for lactate. Transitions in
positive ionization mode were 132.0 → 44.2 and 132.0 →
90.1 for creatine. The gas temperature was 350°C, the flow
rate was 10 l/min, the nebulizer pressure was 50 psi
(≈0.34 MPa),and the capillary voltage was +4000 V. Total
amounts of each metabolite were normalized per mg of
tumor tissue or per cell number as indicated.
Respirometry
The oxygen consumption rate (OCR) and extracellu-
lar acidification rate (ECAR) of cells were measured
using an XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, Massachusetts, USA). In brief, cells were
plated at 5 × 105/well, starved overnight and stimu-
lated with 5% serum for 6 hours. Rates were measured
as previously described [23] at baseline levels. The
data shown correspond to one representative experi-
ment out of three performed and the values represent
an average of six wells.
Analysis of metabolites by gas chromatography and mass
spectrometry (GC-MS)
Water-soluble metabolites were extracted (5 × 106cells/
10 cm dish) and prepared for analysis as described previ-
ously [24,25]. Tricarballylic acid was added as an internal
standard following cell lysis. Extracts were dried using a
chilled vacuum centrifuge (Labconco, Kansas City, MO
USA) and stored at −80°C until GC-MS analysis. Samples
were resuspended in 30 μl anhydrous pyridine and 70 μl
N-tert-butyldimethylsilyl-N-methyltrifluoroacetamide and
incubated at 70°C for 1 hour. The GC-MS data were ac-
quired on an Agilent 5975C series GC/MSD system
(Agilent Technologies, Santa Clara, CA, USA) operating
in electron ionization mode (70 eV) for selected ion moni-
toring. The relative amount of each metabolite was deter-
mined from the integral ratios of the metabolites to the
internal standard and normalized to the number of cells
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Measurement of glucose uptake
Glucose uptake was determined using the fluorescent
glucose analog 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)
amino)-2-deoxyglucose (2-NBDG) following the manufac-
turer’s instructions (Invitrogen, Burlington, ON, Canada).
Briefly, cells were incubated with 100 nM 2-NBDG for
45 minutes and the mean fluorescent intensity was
measured in the FL-2 channel using a Gallios flow
cytometer (Beckman Coulter). The mean fluorescent
intensity was normalized to the basal cellular GFP
fluorescence to correct for differences in GFP expres-
sion between cell lines. The values represent an aver-
age of triplicate samples for each experiment.
RNA extraction, cDNA synthesis, and quantitative PCR
RNA extraction, cDNA synthesis, and quantitative PCR
were performed as previously described [26]. The list of
primers is provided in Additional file 3: Table S2. Experi-
ments were performed in triplicate using three different
cDNA preparations. In each experiment, the NIC-FF
sample served as the reference sample and Rpl13 was used
as the control. Real-time PCR was performed using an
Applied Biosystems 7500 instrument (Applied Biosystems,
Burlington, ON, Canada). The data are represented as the
relative mRNA expression in LKB1 knockdown cells com-
pared with control cells for each individual gene.
Measurement of lactate production
Lactate in culture medium collected from cells cultured for
48 hours, with or without rapamycin treatment (100 nM),
was determined using either the NOVA BioProfile 400
analyzer or the Eton Bioscience kit (Eton Bioscience,
Charlestown, MA,USA) according to the manufacturer’s
instructions. In each case, the resulting data were normal-
ized to the cell number.
Cleaved caspase-3 assay
To assess tumor cell apoptosis in response to metabolic
challenge, 6,000 cells were plated in a 96-well plate and
maintained for 24 hours prior to switching to experi-
mental culture conditions, which included 25 mM or 1
mM glucose each in the presence or absence of
rapamycin (100 nM) for 72 hours. Cells were subse-
quently fixed in 4% paraformaldehyde and washed in
PBS with 0.1% Triton. Endogenous peroxidases were
quenched by treatment with wash buffer plus 1% H2O2.
A cleaved caspase-3 antibody (Cell Signaling Technology,
#9661, Whitby, ON, Canada) was applied for 1 hour at
room temperature (1:250), followed by a 1 hour incuba-
tion with secondary HRP-conjugated, anti-rabbit anti-
bodies. Chemiluminescent reagent was then added anddetected using a plate reader. The resulting chemilumin-
escent signals were then normalized to cell number, which
was determined by performing a crystal violet staining of
the plate and reading the absorbance at 595 nm. The data
shown correspond to one representative experiment out
of three performed and the values represent an average of
six wells.
Viability assay
To assess tumor cell apoptosis in response to metabolic
challenge, cells were plated in 12-well plates and
maintained for 24 hours. Cultures were then switched to
the experimental conditions, which included 25 mM or
1 mM glucose each in the presence or absence of
rapamycin (100 nM) for 72 hours. Cells were then incu-
bated with 7-AAD (eBioscience, San Diego, CA, USA) at
5 μl per sample for 15 min and the fluorescence was
detected with a Gallios flow cytometer in the FL-4 channel
(Beckman Coulter). The percentage of dead cells (7-AAD
positive) was calculated using FlowJo software (Tree Star
Inc.). The data represent one experiment out of three in-
dependent replicates, and are the mean ± standard devi-
ation for triplicate samples.
Statistical analysis
Statistical analyses were run using a two-tailed Student’s
ttest and online software (VassarStats) and the P values
were represented using the following annotation: *, P<
0.05; **, P< 0.01; ***, P< 0.001. The significance of the
tumor growth curves was assessed using analysis of vari-
ance and significance was indicated when the knock-
down population was statistically different from both the
parental and the control cell lines. Data are expressed as
mean ± standard deviation for n ≥ 3.
Results
Loss of LKB1 enhances the development of ErbB-2-induced
mammary tumors
Deletion of LKB1 in the mouse mammary gland has
been shown to result in spontaneous tumor formation
with low penetrance (19%) and long latency (46 to 85
weeks) [4]. To examine the consequences of LKB1 loss
on mammary tumor formation driven specifically by the
ErbB2 oncogene, we crossed mice containing a floxed
LKB1 gene [18] with a MMTV/NIC mouse model that
expresses an activated form of ErbB2 (NDL2-5) and Cre
recombinase from a single bicistronic transgene [19].
This genetic cross was performed to ensure that deletion of
LKB1 occurred in every mammary tumor cell transformed
by ErbB2 in vivo. No significant difference in tumor onset
was observed in NIC/LKB1+/+ mice (T50 = 130 days) when
compared with NIC/LKB1fl/fl animals (T50 = 120 days),
with both cohorts developing palpable tumors at 17 to 18





























































































Figure 1 LKB1 loss promotes the initiation of ErbB2-induced mammary tumors. (A) Kaplan-Meier analysis, depicting the percentage of
tumor-free animals over time in NIC/LKB1+/+and NIC/LKB1fl/fl cohorts. The T50 values represent the time at which 50% of the mice develop their
first palpable mammary tumor. n, number of animals analyzed in each cohort. (B) Number of tumor-bearing mammary glands in each cohort.
The average number of involved glands is increased in NIC/LKB1fl/fl (7.5 ±1.1) compared with NIC/LKB1+/+ mice (5.4 ±1.4) (***, P< 0.001).
(C) Hematoxylin staining of mammary gland whole mounts dissected from 3-month-old NIC/LKB1+/+ and NIC/LKB1fl/fl mice. Arrows indicate the
presence of pre-neoplastic lesions. (D) Mammary tumor growth following mammary fat pad injection of NIC tumor cells harboring shRNAs
targeting FireFly luciferase (NIC-FF) and NIC mammary tumors with stable LKB1 knockdown (NIC-LKB1 KD). NIC-FF or NIC-LKB1 KD cells were
injected in the mammary fat pads of 8-week old SCID/beige mice (n = 10 mice per group) and tumor growth was monitored by bi-weekly
calliper measurements (*, P< 0.05).
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cantly higher in LKB1 mutant mice, with an average of 7.5
involved glands in NIC/LKB1fl/fl mice compared with 5.4
involved glands for NIC/LKB1+/+ animals (Figure 1B). This
result suggests that loss of LKB1 promotes an increase in
the number of ErbB2-dependent transformation events
leading to increased overall tumor formation.
To determine whether the loss of LKB1 is associated
with enhanced tumor initiation, we examined inguinal
mammary gland whole mounts of 3-month-old mice
(prior to the average age at first tumor palpation). This
analysis revealed an increase in the number of pre-
neoplastic lesions in mammary glands of NIC/LKB1fl/fl
mice compared with NIC/LKB1+/+animals (Figure 1C).
To further examine the effects of LKB1 loss on mammary
tumor growth, we used a mammary tumor cell explant
model (herein called ‘NIC’) derived from an MMTV/NIC
transgenic mouse [19]. The NIC cell line was infected with
retroviruses containing control shRNAs (targeting firefly
luciferase, FF) or shRNAs against LKB1 (LKB1 KD). Im-
munoblot analyses revealed that LKB1 levels were effect-
ively diminished in explanted LKB1 shRNA-expressing
NIC mammary tumor cells compared with NIC cells ex-
pressing the control shRNA (see Additional file 4: FigureS1). We next examined the level of suppression of LKB1-
dependent signaling in our shRNA-expressing NIC cell
lines by assessing their responses to metabolic stressors
known to activate LKB1-dependent pathways. Metformin
is an inhibitor of complex I in the mitochondria [27,28],
and leads to LKB1-dependent activation of AMPK [9].
Following metformin treatment, both parental and control
NIC cells displayed an increase in AMPK phosphorylation
at T172 and elevated phosphorylation of the AMPK target
acetyl-CoA carboxylase (ACC) (Additional file 4: Figure
S1). By contrast, LKB1 shRNA-expressing NIC cells
displayed reduced levels of both p-AMPK and pACC rela-
tive to control cells, indicating reduced signaling down-
stream of LKB1.
To determine the effect of diminished LKB1 levels on
mammary tumor growth in vivo, we injected parental
(NIC-p), control (NIC-FF). and LKB1 KD (NIC-LKB1
KD) cells into the mammary fat pads of immunocom-
promised mice. NIC cells expressing LKB1 shRNA
displayed accelerated growth at early time points post-
injection compared with NIC-p and NIC-FF tumor cells
(Figure 1D). However, this initial difference in the
growth of LKB1-deficient tumors was progressively lost
after 30 days (Figure 1D).
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an invasive phenotype
To characterize the effect of LKB1 loss on tumor cell
phenotype further, we next investigated the status of cell
polarity in ErbB2-positive breast cancer cells with re-
duced LKB1 expression. Loss of cell polarity is an im-
portant characteristic for the acquisition of migratory
and invasive phenotypes [29,30] and LKB1 has been pre-
viously linked with the regulation of polarity in a variety
of cellular contexts [31,32]. Mice deficient for LKB1 do
not survive beyond embryonic day E10.5, owing to im-
paired production of vascular endothelial growth factor
and defective vascular development[33]. To investigate
the biological impact of LKB1 down-regulation on junc-

















































































Figure 2 LKB1 knockdown in breast cancer cells causes reduced expr
invasive properties. (A) Representative immunofluorescent images of NIC
E-cadherin (red) and ZO-1 (purple). Nuclei were counterstained with 4',6-di
confirm that breast cancer cells retain expression of the control or LKB1-tar
and applies to all panels. (B) Quantification of the number of cell colonies
staining). The data correspond to an average of three independent experim
and NIC-LKB1 KD cells were assessed using the xCELLigence platform. The
performed in duplicate. *, P< 0.05.analyzed 3D Matrigel cultures of control NIC cells and
NIC cells expressing LKB1 shRNA using confocal mi-
croscopy. By contrast with control NIC cells, which
grow cohesively and exhibit high levels of E-cadherin
and ZO-1 expression, mammary tumor cells with re-
duced LKB1 expression displayed fewer cell contacts and
expressed significantly lower levels of both junctional
markers (Figure 2A). Our analysis of cell colonies that
exhibited strong E-cadherin and ZO-1 staining revealed
that NIC cells with reduced LKB1 expression produced
60% fewer acini with substantial junctional protein expres-
sion (E-cadherin and ZO-1) (Figure 2B), indicating that
reduced LKB1 levels correlate with reduced cell junction
integrity. To assess whether loss of LKB1 affects the mi-






































ession of epithelial markers and acquisition of migratory and
-FF and NIC-LKB1 KD cells in 3D collagen cultures stained with
amidino-2-phenylindole (DAPI) (blue) and GFP images are shown to
geting shRNAs. The scale bar in the upper left inset represents 20 μm
exhibiting strong junctional protein expression (E-cadherin and ZO-1
ents. **, P< 0.01. The migratory (C) and invasive (D) rates of NIC-FF
data represent an average of three independent experiments
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NIC-LKB1 KD cells in vitro using the xCELLigence plat-
form. LKB1 shRNA-expressing NIC cells exhibited en-
hanced migration (Figure 2C) and invasion (Figure 2D)
rates compared with control tumor cells; this is evidence
of a higher invasive phenotype, and is consistent with the
diminished junctional integrity exhibited by these cells.
Loss of LKB1 results in reduced lung metastatic burden
Reduced cell-to-cell contacts and increased migration
and invasion are critical features for efficient metastasis
[29,30]. To assess the impact of LKB1 loss on breast
cancer metastasis, we examined the lung metastatic bur-
den of mice previously subjected to mammary fat pad in-
jections with NIC-FF or NIC-LKB1 KD cells (n = 10
animals per cell line). Approximately 90% of animals for
both cohorts developed lung metastases (Figure 3A).
However, amongst animals presenting lung metastases,
the number of metastases per lung, though lower, was not
significantly affected by the reduction of LKB1 (Figure 3B).
Interestingly, we observed that the size of individual me-
tastases present in the lung of animals injected with NIC
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Figure 3 Loss of LKB1 results in reduced lung metastatic burden. The
lung metastases, the number of lung metastases, the average lesion size an
determined at necropsy on mice subjected to mammary fat pad injection
mice subjected to tail vein injections with NIC-FF and NIC LKB1 KD cells (n
not significant.(Figure 3C), which resulted in a significantly reduced per-
centage of lung surface covered by lesions (Figure 3D).
To investigate this issue further, we conducted an ex-
perimental metastasis assay by injecting NIC tumor cells
expressing control (FF) or LKB1 shRNA (LKB1 KD) via
the tail vein (n = 10 animals per cell line), and assessed
subsequent seeding of tumor cells in the lung. All mice
injected with control NIC breast cancer cells developed
lung metastases, compared with 80% of animals injected
with NIC-LKB1 KD cells developing lung metastases
(Figure 3E). Like the spontaneous metastasis assay, the
number of lung metastases per lung was not significantly
affected by the status of LKB1 (Figure 3F). However,
both the average size of individual metastases (Figure 3G)
and the percentage of lung tissue occupied by metastatic
lesions (Figure 3H) were substantially reduced in animals
that received LKB1 shRNA-expressing tumor cells, com-
pared with mice that received control NIC tumor cells.
LKB1-deficient mammary tumors display a pro-growth
molecular signature
To investigate molecular mechanisms contributing to














































































































percentage of mice within each cohort that developed spontaneous
d the percentage lesion area present per total lung area were
with NIC-FF and NIC LKB1 KD cells (n = 10 mice per group) (A-D) or
= 10 mice per group) (E-H). *, P< 0.05; **, P< 0.01; ***, P< 0.001. n.s.,
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tumors using a reverse phase protein array (RPPA). Five
tumors from each genotype (NIC/LKB1+/+ and NIC/
LKB1fl/fl) were analyzed using a panel of 126 antibodies
[34] (Additional file 5: Table S3). Unsupervised cluster-
ing of the data resulted in a clear segregation between
mammary tumors from NIC/LKB1+/+ mice and those
arising in NIC/LKB1fl/fl animals (see Additional file 6:
Figure S2 and Additional file 1: description of the statis-
tical analysis). As expected, one of the largest differences
was seen in the phosphorylation status of AMPK,
which was severely reduced in all NIC/LKB1fl/fl tumors
(Figure 4A). This result is consistent with the role of
LKB1 as an upstream activator of AMPK [8,9].
LKB1 has been shown to mediate some of its effects
on tumorigenesis through modulation of the mTOR
pathway [32,35]. We observed an increase in ribosomal
S6 protein phosphorylation at both S235/236 and S240/
244, suggesting increased mTOR activity in LKB1-
deficient ErbB2-positive tumors (Figure 4A). Interest-
ingly, LKB1-deficient tumors also displayed increased
Akt activation, as shown by elevated phosphorylation
levels of T308 and S473 in Akt (Figure 4A). Evidence of
elevated mTOR phosphorylation on S2448 and elevated
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Figure 4 LKB1 loss confers a pro-growth signal transduction signatur
NIC/LKB1fl/fl mammary tumors were subjected to RPPAanalysis. Expression
expressed between NIC/LKB1+/+ and NIC/LKB1fl/fl mammary tumors. Color
phospho-proteins that are underexpressed and red identifying those that a
of mammary tumor lysates derived from NIC/LKB1+/+and NIC/LKB1fl/fl mice
signaling pathways. Immunoblot analysis for β-actin serves as a loading coknown Akt phosphorylation sites, was also detected in
NIC/LKB1fl/fl tumors (Figure 4A).
We next validated the results from the RPPA analysis
by immunoblotting mammary tumor lysates derived
from NIC/LKB1+/+ and NIC/LKB1fl/fl mice. As expected,
LKB1 was readily detected in mammary tumors harvested
from NIC/LKB1+/+ mice but absent in NIC/LKB1fl/fl
mammary tumors (Figure 4B). In agreement with our
RPPA analysis (Figure 4A), reduced levels of phosphory-
lated AMPK were detected in LKB1-deficient tumors
(Figure 4B). These phenotypes were also confirmed by
immunohistochemistry (n = 4 mammary tumors from
each cohort) (see Additional file 7: Figure S3). Activation
of Akt in LKB1-deficient mammary tumors was also con-
firmed using phospho-Akt antibodies (Figure 4B). LKB1-
deficient mammary tumors displayed elevated levels of
mTORC1 pathway activation, as measured by increased
pS6 and hyperphosphorylated 4E-BP1 by immunoblot
analysis (Figure 4B) and immunohistochemistry (see
Additional file 8: Figure S4 and Additional file 1: de-
scription of methods). Interestingly, immunohisto-
chemistry revealed that loss of LKB1 did not increase
the intensity of staining for pS6 and p4E-BP1 in
mammary tumors; rather the total number of cells




























e in ErbB2-positive mammary tumors. (A) Five NIC/LKB1+/+and five
of selected proteins and phospho-proteins that are differentially
key indicates level of expression, with green signifying proteins and
re overexpressed compared with control cells. (B) Immunoblot analysis
with antibodies directed to components of the mTOR and Akt
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LKB1 (see Additional file 8: Figure S4). Collectively
these results indicate that tumors lacking LKB1 dis-
play a protein activation signature associated with
pro-growth PI3K/Akt/mTOR signaling.
Loss of LKB1 promotes the Warburg effect and increased
bioenergetics in ErbB2-positive mammary tumors
Our results from Figure 4 suggest that mammary tumors
lacking LKB1 display increased mTOR and Akt signaling.
Besides its well-characterized role in promoting cell sur-
vival and growth, Akt/mTOR signaling can also stimulate
metabolic pathways, such as aerobic glycolysis in cancer
cells [36]. To assess the effects of LKB1 loss on the metab-
olism of ErbB2-positive tumors, we characterized the bio-
energetic profiles of primary ErbB2-positive tumors using
LC-MS analysis (Figure 5). LKB1-deficient breast tumors
displayed increased intracellular levels of glucose





































































































Figure 5 Loss of LKB1 results in increased bioenergetic markers in Er
NIC/LKB+/+ and six NIC/LKB1fl/fl mammary tumors were subjected to LC-MS
(D), ADP (E), and AMP (F) are represented as μM per mg of tumor. (G-J) N
(A-F). Intracellular levels of ATP (G), ADP (H) and AMP (I) are represented i
relative to the ratio for control cells. *, P< 0.05; **, P< 0.01.the Warburg effect [37]. We also observed statistically
higher levels of energy storage molecules, including creat-
ine (Figure 5C), ATP (Figure 5D), and ADP (Figure 5E) in
LKB1-deficient tumors, while the levels of AMP, which is
a low-energy metabolite, were not affected by LKB1 status
(Figure 5F). We next confirmed these results in our cell
line models. We observed a 50% increase in the level of
ATP (Figure 5G) in LKB1-deficient cells compared with
control cells; the levels of ADP (Figure 5H) and AMP
(Figure 5I), although higher in LKB1 KD cells, were
not statistically significant. Consequently, the AMP:
ATP ratio was not statistically different in cells with
normal or reduced LKB1 expression (Figure 5J). Together
these data indicate that LKB1 loss enhances the bioener-
getic profile of primary mammary tumors.
To assess the impact of LKB1 loss on the metabolism
of ErbB2-positive breast tumors, we conducted bioener-
getic profiling of NIC tumor cells in vitro using an extra-















































































bB2-positive mammary tumors and derived cell lines. (A-F) Six
analysis. Intracellular levels of glucose (A), lactate (B), creatine (C), ATP
IC-FF and LKB1 KD cells were subjected to metabolic analyses as in
n μM per 106 cells. The AMP:ATP ratio (J) in LKB1 KD cells is expressed
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http://www.cancerandmetabolism.com/content/1/1/18expression (NIC-LKB1 KD) displayed a two-fold increase
in their elevated ECAR, an index of lactate production
[38], relative to control NIC cells (ECAR, Figure 6A).
However, loss of LKB1 did not affect oxygen consump-
tion by NIC cells (OCR, Figure 6B), consistent with ob-
servations that oxygen consumption is largely normal in
cells undergoing the Warburg effect [39]. Consistent
with an increased ECAR, LKB1-deficient NIC cells
displayed an increase in both extracellular (Figure 6C)
and intracellular (Figure 6D) lactate levels when com-
pared with control tumor cells.
We next examined the expression of genes encoding en-
zymes involved in glycolysis using quantitative PCR.
LKB1-deficient cells displayed a significant increase in the









































































Figure 6 LKB1-deficient breast cancer cells display increased aerobic
NIC-LKB1 KD cells were plated for ECAR (A) and OCR (B) analyses. The data
replicates and the values correspond to an average of five wells per experi
and the relative extracellular (C) and intracellular (D) levels of lactate were d
data represent one representative experiment from three independent rep
NIC-FF and NIC-LKB1 KD cells, and the relative mRNA expression of several
determined relative to Rpl13 (60S ribosomal protein L13) mRNA levels, and
represent the average of three independent experiments, each performed
measured by flow cytometry using the 2NBDG fluorescent glucose analog.
independent replicates, each performed in triplicate. *, P< 0.05; **, P< 0.01;including Glucose transporter 1 (Glut1), Glucose trans-
porter 8 (Glut8), Hexokinase 2 (Hk2), Aldolase A (Aldo-A),
Lactate dehydrogenase A (LDHA) and Pyruvate dehydro-
genase kinase 1 (PDHK1) (Figure 6D). The elevated levels
of lactate and increased expression of glycolytic genes ob-
served in LKB1-depleted NIC cells is consistent with the
increased glucose and lactate levels observed in primary
mammary tumors (Figure 5). We then assessed the signifi-
cance of increased glucose transporter expression by
measuring the level of glucose uptake by our NIC cells.
Using the 2NBDG fluorescent glucose analog, we demon-
strate that LKB1-deficient cells exhibit a 2.3-fold increase
in glucose uptake relative to control NIC cells. This result
is in agreement with the observed increase in lactate pro-






































































glycolysis. (A-B) Extracellular flux analysis of NIC cell lines. NIC-FF and
represent one representative experiment of three independent
ment. (C-D) NIC-FF and NIC-LKB1 KD cells were cultured for 48 hours
etermined using an enzymatic assay and GC-MS, respectively. The
licates, each performed in triplicate. (E) Total RNA was isolated from
glycolytic enzymes was determined by qPCR. Transcript levels were
normalized relative to its expression in control NIC-FF cells. The data
in triplicate. (F) Glucose uptake in NIC-FF and NIC-LKB1 KD cells was
The data correspond to one representative experiment out of four
***, P< 0.001.
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stress
Cells with deregulated mTOR signaling, such as TSC2-
null cells, gain a metabolic growth advantage, but also dis-
play increased sensitivity to metabolic stresses including
glucose deprivation [40]. ErbB2-driven breast tumors lack-
ing LKB1 display elevated mTORC1 activity (Figure 4).
We first validated that the selected concentration of
rapamycin and duration of treatment were sufficient to in-
hibit mTOR activity in our cells. Immunoblot analysis
confirmed the efficacy of the inhibitor, as revealed by the
loss of S6 phosphorylation and the accumulation of
hypophosphorylated forms of 4E-BP1 (Figure 7A). To as-
sess whether the loss of LKB1 leads to mTOR-dependent
glucose addiction in breast cancer, we analyzed the glyco-
lytic profile of NIC tumor cells in response to glucose
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Figure 7 Loss of LKB1 sensitizes cells to metabolic stress. (A) Immuno
KD cells treated with rapamycin (100 nM) for 24 hours to confirm mTOR ac
(B-C) ECAR analysis of NIC-FF and NIC-LKB1 KD cells treated or not with rap
conditions (C). (D) ECAR analysis of NIC-FF and NIC-LKB1 cells treated with
were performed on NIC-FF and NIC-LKB1 KD cells cultured in 25 mM glucose o
The level of apoptosis was assessed using 7-AAD (E) or cleaved caspase 3 leve
performed, and values represent the average of six wells for (B), (C), (D) and (F
for 24 hours in 1 mM glucose and intracellular ATP levels were quantifie
glucose). *, P< 0.05; **, P< 0.01; ***, P< 0.001.expressing LKB1 shRNA displayed an elevated ECAR
compared with control cells (Figure 7B). Reducing glucose
in the culture medium to 1 mM lead to a 60% drop in the
ECAR of control cells (Figure 7C); importantly, LKB1-
deficient cells dropped their ECAR by only 40% in re-
sponse to low glucose and maintained an ECAR roughly
equivalent to control cells under full growth conditions
(Figure 7B, C). The enhanced lactate production by LKB1-
deficient NIC cells was dependent on mTORC1 activity,
as the ECAR of control and LKB1 KD cells was equivalent
when cells were treated with the mTORC1 inhibitor
rapamycin (Figure 7B, C). Direct measurement of
extracellular lactate levels confirmed an increase in
lactate production by LKB1-deficient NIC cells and the
ablation of this glycolytic phenotype by rapamycin
treatment (see Additional file 9: Figure S5). These data
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blotting was performed on protein extracts from NIC-FF and NIC-LKB1
tivity. Arrows point to the hypophosphorylated forms of 4E-BP1.
amycin for 24 hours in full glucose conditions (B) or in 1 mM glucose
vehicle or with metformin (5 mM) for 6 hours. (E-F). Viability assays
r 1 mM glucose and treated or not treated with rapamycin for 72 hours.
ls (F). All graphs correspond to a representative experiment of three
) and three wells for (E). (G) NIC-FF and NIC-LKB1 KD cells were cultured
d as the percentage drop from baseline conditions (25 mM of
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positive tumor cells.
To study the metabolic flexibility of breast cancer cells
lacking LKB1, we treated ErbB2-positive tumor cells
with the complex I inhibitor metformin and investigated
its impact on ECAR. Immunoblot analysis confirmed
that metformin increased AMPK phosphorylation over
time, which was coincident with reduced S6 phosphoryl-
ation and accumulation of the hypophosphorylated form
of 4E-BP1 (see Additional file 10: Figure S6). Metformin
could suppress mTORC1 activity in both control and
LKB1 KD cells, although this effect was delayed in cells
expressing LKB1 shRNA. While metformin stimulated
an increase in glycolysis in control tumor cells, LKB1-
deficient cells were unable to respond to metformin by
increasing their ECAR (Figure 7D).
Finally, we assessed the apoptotic response of LKB1-
deficient NIC cells in response to energetic stress.
Tumor cells lacking LKB1 displayed increased apoptosis,
as measured by 7-AAD (Figure 7E) and Caspase-3 acti-
vation (Figure 7F), when cultured under low glucose
conditions. Rapamycin protected LKB1-deficient NIC
cells from apoptosis induced by glucose deprivation
(Figure 7E and 7F), suggesting that dampening mTORC1
signaling in these tumor cells can confer protection from
nutrient limitation. In agreement with an increased sensi-
tivity to glucose depletion, we observed a more dramatic
drop in intracellular ATP levels within LKB1-deficient cells
(72% reduction) compared with the control cells (40%
reduction) when cultured for 24 hours in 1 mM glucose
(Figure 7G). These results suggest that LKB1-deficient
cells are unable to maintain cellular ATP levels in
response to energetic stress, promoting an increase in
cell death.
Discussion
LKB1 is a central growth-regulatory kinase that exerts
its effects, in part, through the negative regulation of
pro-growth pathways such as mTOR. LKB1 is a well-
established tumor suppressor, with both germline and
somatic mutations in STK11, the gene encoding LKB1,
associated with cancer development. While broadly
linked with cancer, LKB1’s role in breast cancer develop-
ment and metabolic regulation in primary tumors has
been poorly understood. To address this question, we
created a genetically engineered mouse model to assess
the impact of LKB1 deletion on the development and
progression of breast tumors driven by the ErbB2 onco-
gene. We observed that ErbB2-mediated breast tumori-
genesis is enhanced by LKB1 deletion, which is consistent
with both experimental and clinical data linking LKB1 to
breast cancer [41,42]. Recent work by Andrade-Vieira and
colleagues [6] also investigated the role of LKB1 in ErbB2-
mediated tumorigenesis using a similar mouse strain(stk11−/−; NIC). They observed a ~ 25% decrease in tumor
latency, which was not apparent in our model. We ob-
served a ~ 8% reduction in median tumor latency that was
not statistically significant (Figure 1A). However, detailed
whole-mount analysis of our mice revealed the presence
and early onset of hyperplastic lesions in the mammary
epithelium when LKB1 was absent (Figure 1C). This ob-
servation was similar to the growth advantage displayed
by LKB1-knockdown NIC tumor cells in vivo at early time
points (Figure 1D). Thus, despite differences in tumor la-
tency, both models indicate that LKB1 loss can cooperate
with ErbB2 to promote breast tumor initiation. Our data
suggest that the prominent phenotypic changes associated
with LKB1-deletion in breast tumors are a reprogramming
of signal transduction and metabolic pathways to favor in-
creased bioenergetic capacity and cell growth.
Our work and that of other groups [43] suggests that
loss of LKB1 cooperates with oncogenes to modulate the
initiation and growth properties of tumors; however, our
data indicate that the impact of reducing LKB1 expression
on breast cancer development is complex. LKB1 deletion
in mammary tissue promotes the induction of mammary
tumors with low penetrance and long latency [4],
suggesting that LKB1 deletion or loss-of-heterozygosity
may not be a significant driving event for breast can-
cer. In contrast, deletion of STK11 in MYC-driven
breast tumor models significantly reduced the latency
period for tumor development [5]. In the context of tu-
mors driven by unregulated ErbB2 signaling, complete
loss of LKB1 does not affect the latency of tumor forma-
tion driven by the ErbB2 oncogene; rather, it increases the
total number of pre-neoplastic lesions and overt tumors
that form in these animals. Thus, while ErbB2 may drive
the establishment of primary tumors, increased cell
growth, and deregulated metabolism, the differences ob-
served between the ErbB2 model and that of other groups
may reflect differences in the mechanisms by which ErbB2
promotes tumor development relative to other oncogenes.
Both PI3K, which is activated by ErbB2, and MYC are
strong drivers of metabolism; thus loss of LKB1 may
synergize specifically with these oncogenes by enhancing
pro-growth metabolic pathways.
One of the striking features observed in primary
LKB1-deficient ErbB2-postive breast tumors is the amp-
lification of signal transduction pathways impacting cell
growth and metabolism. ErbB2 is an oncogenic receptor
tyrosine kinase that initiates signaling pathways that
control both cell proliferation and survival, including
MAPK/ERK and PI3K/Akt pathways [17]. Using RPPA
analysis to detect changes in signal transduction path-
ways in primary breast tumors, we observed major shifts
in cellular signaling specifically in primary LKB1-
deficient ErbB2-positive breast tumors. Consistent with
previously established roles for LKB1, deletion of LKB1
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signaling in ErbB2-positive breast tumors. However, we
also observed evidence of enhanced signaling by other ki-
nases including Src, MEK1, and MAPK, suggesting a pre-
viously unappreciated negative regulatory role of LKB1 on
these pathways. Importantly, reducing AMPK activity may
not be the only means by which mTOR activity is elevated
in LKB1-deficient tumors. Akt is a direct activator of
mTOR, and both Akt phosphorylation (T308/S473) and
phosphorylation of Akt targets (GSK3β, PRAS40) were
elevated in ErbB2-positive tumors lacking LKB1. By re-
moving an endogenous repressor of both mTOR and
Akt activity, LKB1 loss may be one way for oncogenic
ErbB2 to reprogram signal transduction in tumors to
promote metabolism and increased cell growth during
transformation.
One of the mechanisms by which oncogenes promote
tumor cell growth and proliferation is through enhanced
activation of key metabolic pathways, such as glycolysis
[44]. Here we show that loss of LKB1 in ErbB2-mediated
breast cancer is sufficient to promote the Warburg ef-
fect. ErbB2-positive breast cancer cells lacking LKB1
displayed increased expression of several enzymes and
transporters that support glycolysis, and both glycolytic
flux and overall lactate production were enhanced in
LKB1-deficient breast cancer cells. The enhanced glyco-
lytic metabolism observed in LKB1-deficient breast cancer
cells was reversed by mTORC1 inhibition, suggesting that
elevated mTOR signaling downstream of LKB1 drives the
metabolic phenotype of these cancers. We also observed
hallmarks of the Warburg effect, notably increased
intratumor glucose and lactate levels, in primary
LKB1-deficient ErbB2-postive tumors, suggesting that
LKB1 regulates glucose metabolism in tumors in situ.
This is consistent with previous work showing en-
hanced glucose uptake by fluorodeoxyglucose (18F)
positron emission tomography in benign LKB1+/−
colon polyps [45]. Metabolic analysis also revealed that
LKB1 loss promotes an increased bioenergetic state in
ErbB2-positive tumors; the level of energy storage me-
tabolites, particularly ATP and creatine, were elevated
in LKB1-null tumors. Thus, silencing LKB1 may prime
breast cancer cells for growth by modulating pro-
growth glycolytic metabolism and enhancing ATP pro-
duction and/or storage.
Given the role of LKB1 as a regulator of several pro-
tein kinase pathways, its loss likely affects multiple bio-
logical pathways in tumors in addition to metabolism.
Epithelial integrity is an important parameter for tissue
homeostasis, and loss of epithelial integrity as well as
disruption of normal cellular polarization is often a pre-
cursor to metastasis [5,29]. Our data suggest that loss of
LKB1 leads to altered cell junction formation, reduced ex-
pression of epithelial markers, and increased migratoryand invasive properties of breast cancer cells in vitro. It is
unclear whether the metabolic changes induced by LKB1
loss contribute significantly to these phenotypes.
Clinical data shows LKB1 loss in more invasive can-
cers and in vitro data suggests association between loss
of LKB1 and acquisition of pro-migratory and pro-
invasive properties [46-48], However, despite these pro-
growth and pro-metastatic phenotypes, we consistently
observed a decrease in the ability of LKB1-deficient
breast cancer cells to grow as metastases in the lung
(Figure 3), suggesting that LKB1 is required for efficient
tumor cell growth in a metastatic setting. The dimin-
ished lung metastatic burden in animals with LKB1-null
ErbB2 breast tumors raises interesting questions regard-
ing the fitness of LKB1-deficient tumor cells. The meta-
static process represents a major energetic stress for the
cells as they leave their native environment, travel
through the blood, and ultimately seed in a new organ,
where they must adapt to a new environment. Recent
evidence suggests that LKB1 may be required for pri-
mary tumors to adapt to and survive metabolic stress.
Models of mutant K-ras-driven lung tumorigenesis dem-
onstrate that LKB1 loss accelerates lung tumor formation
[43], but these tumors display increased sensitivity to
apoptosis induced by the metabolic stressor phenformin
[49]. Consistent with these observations, we find that
LKB1-deficient breast cancer cells are increasingly sensi-
tive to glucose limitation. Likewise, LKB1-null NIC cells
are unable to adapt their metabolism when challenged
with the mitochondrial inhibitor metformin. The mecha-
nisms that underlie this increased sensitivity to metabolic
stress are still being examined.
One interesting aspect of the data presented here is
that LKB1-deficient breast tumors display heightened
energetics at the primary site, but appear to require
LKB1 for efficient metastasis to the lung. It is possible
that loss of LKB1 locks these cells into a specific mode
of pro-growth metabolism, making them less able to
adapt to changing tumor or metastatic microenviron-
ments with fluctuating nutrient supply. ErbB2-positive
breast tumor cells lacking LKB1 appear to exist in a pro-
growth state of growth (that is, elevated Akt/mTOR, in-
creased glycolysis); as demonstrated in Figure 7, these
cells continue to maintain a pro-growth state even in the
face of reduced nutrient availability. This may explain
why dampening the pro-growth state of LKB1-null
breast tumor cells, with rapamycin or similar agents, en-
hances their survival under low glucose conditions.
Thus, despite its anti-proliferative effects, LKB1 may
confer metabolic flexibility to tumor cells as they
colonize and attempt to re-initiate growth in a foreign
microenvironment. Collectively our data suggest that in
breast cancer LKB1 represents a molecular switch that
can regulate breast tumor growth in a stage-dependent
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tumorigenesis and early-stage growth in the primary site,
but attenuates the growth of breast cancer cells as lung
metastases.
Conclusions
While loss of LKB1 expression has previously been
linked to breast cancer, the exact role of LKB1 in regu-
lating breast cancer development and metabolism has
remained unclear. Here we demonstrate that loss of
LKB1 increases ErbB2-driven mammary tumor initiation
and early-stage tumor growth. Reducing LKB1 expres-
sion in ErbB2-expressing tumors promotes a pro-growth
molecular and phenotypic signature characterized by
elevation of Akt and mTORC1 signaling, a metabolic
shift towards aerobic glycolysis (Warburg effect), disrup-
tion in junctional integrity, and increased migratory and
invasive properties in vitro. However, despite the pro-
growth signature displayed by LKB1-deficient mammary
tumors, LKB1-deficient breast tumor cells failed to
metastasize the lungs efficiently. We postulate that
LKB1 functions as a metabolic master switch in breast
cancer. Loss or silencing of LKB1 promotes a switch to
the Warburg effect and pro-growth metabolic program
to support increased bioenergetic and biosynthetic de-
mand during ErbB2-mediated breast tumor initiation
and progression.
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knockdown (NIC-LKB1 KD). NIC mammary tumor explants were serum
starved overnight and then stimulated with serum alone or serum
combined with metformin (5 mM) for 1 or 6 hours. Immunoblot analysis
was performed using antibodies against phospho-AMPK (p-AMPK), total
AMPK (AMPK) and phospho-ACC (p-ACC). Immunoblotting for α-tubulin
served as a loading control.
Additional file 5: Table S3. RPPA data corresponding to the heatmap
(126 antibodies).
Additional file 6: Figure S2. LKB1 loss confers a pro-growth signal
transduction signature in ErbB2-positive mammary tumors. Five NIC/LKB1
+/+ and five NIC/LKB1fl/fl mammary tumors were subjected to RPPA
analysis. Unsupervised hierarchical clustering identifies distinct protein
and phospho-protein expression patterns in NIC/LKB1+/+ versus NIC/
LKB1fl/fl mammary tumors. The color key indicates level of expression,
with green signifying proteins and phospho-proteins that are
underexpressed and red identifying those that are overexpressed.Additional file 7: Figure S3. Immunohistochemical staining of
mammary tumors arising in NIC/LKB1+/+ and NIC/LKB1fl/fl mice, using
antibodies against phospho-AMPK (p-AMPK) and total AMPK (AMPK). The
scale bar within the upper left inset represents 20 μm and applies to
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μm and applies to all panels.
Additional file 8: Figure S4. Immunohistochemical staining of
mammary tumors arising in NIC/LKB1+/+ and NIC/LKB1fl/fl mice, using
antibodies against phospho-S6 (p-S6), total S6 (S6), phospho-4E-BP1
(p-4E-BP1) and total 4E-BP1 (4E-BP1). The scale bar within the upper left
inset represents 20 μm and applies to insets in all panels. The scale bar in
the upper left panel represents 150 μm and applies to all panels.
Additional file 9: Figure S5. NIC-FF and NIC-LKB1 KD cells were
treated with or without rapamycin (100 nM) for 48 hours in 25 mM of
glucose, and extracellular levels of lactate were measured in conditioned
media using an enzymatic assay (Eton Bioscience kit). The data
correspond to one representative experiment from three independent
replicate, each performed in triplicate.
Additional file 10: Figure S6. Protein extracts were prepared from NIC-
FF and NIC-LKB1 KD cells treated with metformin (100 nM) for 6, 12, and
24 hours. Immunoblotting was performed to assess the inhibition of
mTOR activity (pS6/S6; mobility shift in 4E-BP1) and the activation of
AMPK (pAMK/AMPK) following metformin treatment. Immunoblotting for
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